SEC Filing Summary: Capricor Therapeutics, Inc. (CAPR)
Business Context and Reporting Period
This Form 8-K, filed on August 7, 2023, serves as a current report for Capricor Therapeutics, Inc., a Delaware corporation. The filing announces the issuance of a press release detailing financial results for the quarter ended June 30, 2023. The company is listed on the Nasdaq Capital Market under the symbol CAPR.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document. The actual figures are contained in the attached press release (Exhibit 99.1), which is referenced but not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes in financial condition or operations compared to prior periods. It only confirms that such results were announced via a press release on the filing date.
Guidance, Outlook, and Risks
The filing references a corporate update included in the attached press release (Exhibit 99.1). However, the text of this Form 8-K does not contain specific guidance, management commentary, risk factors, or details on unusual items. The information is explicitly furnished and not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for specific Q2 2023 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the corporate update.
- Confirm if there were any changes in capital structure or financing activities during the quarter.